Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.87 USD
Change Today +0.03 / 3.57%
Volume 8.0K
SVON On Other Exchanges
Symbol
Exchange
OTC BB
As of 2:14 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

sevion therapeutics inc (SVON) Snapshot

Open
$0.86
Previous Close
$0.84
Day High
$0.87
Day Low
$0.86
52 Week High
06/2/14 - $3.25
52 Week Low
12/3/14 - $0.51
Market Cap
14.3M
Average Volume 10 Days
45.7K
EPS TTM
$-1.12
Shares Outstanding
16.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEVION THERAPEUTICS INC (SVON)

Related News

No related news articles were found.

sevion therapeutics inc (SVON) Related Businessweek News

No Related Businessweek News Found

sevion therapeutics inc (SVON) Details

Sevion Therapeutics, Inc., a biopharmaceutical company, engages in building and developing a portfolio of therapeutics for the treatment of cancer and immunological diseases. The company’s product candidates are derived from multiple proprietary technology platforms, including cell-based arrayed antibody discovery, ultralong antibody scaffolds, and Chimerasome nanocages. Its product pipeline includes VN-001, an ion channel blocking antibody against autoimmune disorders, including rheumatoid arthritis, psoriasis, and multiple sclerosis; SVN-002, an antibody against an oncology target; and SVN-003, a chimerasome/insulin product, which preferentially delivers insulin to the liver. The company was formerly known as Senesco Technologies, Inc. and changed its name to Sevion Therapeutics, Inc. in September 2014. Sevion Therapeutics, Inc. was founded in 1964 and is based in San Diego, California.

13 Employees
Last Reported Date: 09/29/14
Founded in 1964

sevion therapeutics inc (SVON) Top Compensated Officers

Scientific Founder
Total Annual Compensation: $67.5K
Chief Scientific Officer and Director
Total Annual Compensation: $23.1K
Compensation as of Fiscal Year 2014.

sevion therapeutics inc (SVON) Key Developments

Sevion Therapeutics, Inc. Announces Executive Changes

Sevion Therapeutics, Inc. announced that on May 12, 2015, Joel Brooks delivered notice of his resignation as Chief Financial Officer, Secretary and Treasurer, effective May 15, 2015. The Board accepted Mr. Brooks’ notice of resignation. Mr. Schmidt will be appointed to the positions of Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer of the company. Prior to Mr. Schmidt’s engagement by the company, he was providing independent financial consulting services to start-up and growing companies. He formerly served as the Vice President, Finance and Administration of Receptos, Inc. from 2009 to 2013.

Sevion Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended March 31, 2015

Sevion Therapeutics, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended March 31, 2015. For the quarter, loss from operations was $1,224,995 against $2,128,943 a year ago. Loss applicable to common shares was $1,236,431 against $5,024,265 a year ago. Basic and diluted net loss per common share was $0.09 against $0.87 a year ago. For the nine months, licensing revenue was $37,500 against $100,000 a year ago. Loss from operations was $17,157,709 against $5,470,579 a year ago. Loss applicable to common shares was $17,198,584 against $8,470,476 a year ago. Basic and diluted net loss per common share was $1.24 against $2.21 a year ago.

Sevion Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended December 31, 2014; Announces Impairment of Goodwill for the Second Quarter Ended December 31, 2014

Sevion Therapeutics, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended December 31, 2014. For the quarter, the company reported loss from operations of $10,747,122 against $1,588,907 a year ago. Net loss was $10,746,127 against $1,619,638 a year ago. Loss applicable to common shares was $10,763,849 against $1,640,255 a year ago. Basic and diluted net loss per common share was $0.78 against $0.48 a year ago. This increase in the loss applicable to common shares was primarily the result of the impairment of goodwill, and an increase in research and development expenses and general and administrative expenses. For the six months, the company reported loss from operations of $15,932,714 against $3,341,636 a year ago. Net loss was $15,929,934 against $3,403,971 a year ago. Loss applicable to common shares was $15,962,156 against $3,446,211 a year ago. Basic and diluted net loss per common share was $1.15 against $1.20 a year ago. During the second quarter 2015, due to the decline of the company's market value, the company recorded an impairment to goodwill in the amount of $8.1 million.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SVON:US $0.87 USD +0.03

SVON Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for SVON.
View Industry Companies
 

Industry Analysis

SVON

Industry Average

Valuation SVON Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 312.7x
Price/Book 1.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales 354.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEVION THERAPEUTICS INC, please visit www.seviontherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.